Europe: Court awards compensation to Acteon for nullity proceedings

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Europe: Court awards compensation to Acteon for nullity proceedings

In a recent ruling by the Court of The Hague (ECLI:NL:RBDHA:2018: 4591) a defendant/patentee has been ordered to pay the costs of nullity proceedings brought against it, despite not wishing to maintain or assert its patent.

Following infringement proceedings instituted in Germany by Dürr Dental based on European patent EP 1 9292 371 B1 against Acteon, the latter company, active in the same field, started nullity proceedings in the Netherlands against the Dutch part of this patent. Instead of providing arguments against the nullity attacks, Dürr Dental said that it had been, and still was, willing to withdraw the Dutch part of the patent. However, due to the pending proceedings, withdrawal of the patent was not possible anymore without the consent of Acteon. Acteon refused to give this. On the basis of this alleged lack of collaboration on the part of Acteon, Dürr Dental argued that Acteon had to bear the costs of the proceedings, brought without a preliminary warning and considered avoidable by Dürr Dental, and that Article 1019h Rv was not applicable in this case.

As a reminder, Article 1019h Rv provides for a reimbursement of costs by the losing party in IP cases. However, case law stipulates that this is not valid for nullity proceedings, except if the nullity proceedings are a defence against an infringement action or can be considered as a prospective defence of non-infringement.

In the absence of a defence, the Court revoked the Dutch part of the patent. With respect to the argument that the proceedings could have been avoided if Acteon had preliminarily warned Dürr Dental, the Court pointed to the fact that Dürr Dental had been paying annuities for several years to maintain the Dutch part of the patent. At the same time, the Court was of the opinion that in light of the infringement proceedings instituted by Dürr Dental in Germany, Acteon had rightfully started the Dutch nullity proceedings as a prospective defence of non-infringement. However, as Dürr Dental had immediately indicated that it did not wish to defend the Dutch part of its European patent, the Court ruled that only the costs incurred by Acteon until the writ was served, were to be borne by Dürr Dental.

Thus, even if a patentee indicates that it does not wish to exercise its patent rights, it can still be ordered to pay the costs of the proceedings.

Eva Eulaers

V.O.

Carnegieplein 5, 2517 KJ

The Hague

The Netherlands

Tel: +31 70 416 67 11

Fax: +31 70 416 67 99

info@vo.eu

www.vo.eu

more from across site and SHARED ros bottom lb

More from across our site

AG Barr acquires drinks makers Fentimans and Frobishers, in deals worth more than £50m in total
Tarun Khurana at Khurana & Khurana says corporates must take the lead if patent filing activity is to truly translate into innovation
Michael Moore, head of legal at Glean AI, discusses how in-house IP teams can use AI while protecting enforceability
Counsel for SEP owners and implementers are keeping an eye on the case, which could help shape patent enforcement strategy for years to come
Jacob Schroeder explains how he and his team secured victory for Promptu in a long-running patent infringement battle with Comcast
After Matthew McConaughey registered trademarks to protect his voice and likeness against AI use, lawyers at Skadden explore the options available for celebrities keen to protect their image
The Via members, represented by Licks Attorneys, target the Chinese company and three local outfits, adding to Brazil’s emergence as a key SEP litigation venue
The firm, which has revealed profits of £990,837, claims it is the disruptive force in the IP-legal industry
In the first of a two-parter, lawyers at Santarelli analyse the patentability of therapeutic inventions where publication of clinical trial protocols occurs before the application's filing date
Arun Hill at Clarivate assesses the Top 100 Global Innovators 2026 list, including why AI has assumed a strategic importance for innovation
Gift this article